Dogwood Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.20 | -0.15 | +25.00% |
| 2026-03-18 | -0.86 | -0.26 | +69.77% |
| 2025-11-06 | -1.58 | -8.20 | -417.90% |
| 2025-08-13 | -1.90 | -1.99 | -4.74% |
| 2025-05-08 | -0.76 | -8.45 | -1004.58% |
| 2025-03-14 | -1.41 | -6.29 | -344.52% |
| 2024-11-07 | -1.18 | -2.05 | -74.22% |
| 2024-08-08 | -1.58 | -1.25 | +21.05% |
| 2024-05-09 | -1.00 | -1.75 | -75.00% |
| 2024-02-29 | -2.25 | -1.50 | +33.33% |
| 2023-11-13 | -2.25 | -1.50 | +33.33% |
| 2023-08-10 | -1.25 | -2.00 | -60.00% |
| 2023-05-12 | -4.00 | -1.29 | +67.68% |
| 2023-03-14 | -3.75 | -2.75 | +26.67% |
| 2022-11-14 | -11.50 | -7.00 | +39.13% |
| 2022-08-11 | -12.25 | -11.00 | +10.20% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DWTX | +15.75% | -42.32% | -59.38% | -67.37% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +12.78% | -37.68% | -55.93% | -80.06% |